- Home
- DSGN vs APPS Comparison
DSGN vs APPS Comparison
Compare DSGN & APPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- APPS
- Stock Information
- Founded
- DSGN 2017
- APPS 2007
- Country
- DSGN United States
- APPS United States
- Employees
- DSGN N/A
- APPS N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- APPS Multi-Sector Companies
- Sector
- DSGN Health Care
- APPS Miscellaneous
- Exchange
- DSGN Nasdaq
- APPS Nasdaq
- Market Cap
- DSGN 224.8M
- APPS 243.8M
- IPO Year
- DSGN 2021
- APPS N/A
- Fundamental
- Price
- DSGN $3.98
- APPS $4.62
- Analyst Decision
- DSGN Hold
- APPS Hold
- Analyst Count
- DSGN 1
- APPS 3
- Target Price
- DSGN $4.00
- APPS $2.33
- AVG Volume (30 Days)
- DSGN 91.9K
- APPS 3.3M
- Earning Date
- DSGN 05-07-2025
- APPS 06-10-2025
- Dividend Yield
- DSGN N/A
- APPS N/A
- EPS Growth
- DSGN N/A
- APPS N/A
- EPS
- DSGN N/A
- APPS N/A
- Revenue
- DSGN N/A
- APPS $483,577,000.00
- Revenue This Year
- DSGN N/A
- APPS N/A
- Revenue Next Year
- DSGN N/A
- APPS $6.49
- P/E Ratio
- DSGN N/A
- APPS N/A
- Revenue Growth
- DSGN N/A
- APPS N/A
- 52 Week Low
- DSGN $2.60
- APPS $1.18
- 52 Week High
- DSGN $7.77
- APPS $6.86
- Technical
- Relative Strength Index (RSI)
- DSGN 53.86
- APPS 61.30
- Support Level
- DSGN $3.67
- APPS $4.31
- Resistance Level
- DSGN $4.13
- APPS $5.19
- Average True Range (ATR)
- DSGN 0.30
- APPS 0.38
- MACD
- DSGN 0.05
- APPS -0.01
- Stochastic Oscillator
- DSGN 85.78
- APPS 49.56
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.